SLDB Solid Biosciences Inc

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louise Perry, Head of Technical Operations, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 10:30 am ET.

A live webcast of the fireside chat will be available on the Company’s investor relations website, under the Events page accessible here: . A replay will be available on the Company's website following the event.

About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit .

Investor Contact:

David Carey

FINN Partners

212-867-1768

Media Contact:

Erich Sandoval

FINN Partners

917-497-2867



EN
20/04/2021

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted stock units (“RSUs”) to four newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s...

October 1, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at Upcoming Scientific Meetings CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from its neuromuscular and cardiac programs at the World Muscle Society (WMS) 2025 Annual International Congress, October 7-11, 2025, in Vienna, Austria, and at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress, October 7-12, 2025, in Seville, Spain. “Our presentations at WMS and ESGCT will high...

October 1, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual ...

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation investigational gene therapy intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG), September 26-28, 2025, in Stresa, Ita...

September 25, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the...

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass...

September 23, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Citi Biopharma Back to School ConferenceBo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 2, 2025, at 1:45 p.m. ET. A live webcast will be available by . Cantor Global Healthcare ConferenceMr. ...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch